论文部分内容阅读
霉酚酸酯(MMF)是霉酚酸(MPA)的2-乙酰基衍生物, 是一种新型的免疫抑制剂,可选择性抑制增殖性T和B淋巴细胞,从而抑制体液免疫和细胞免疫。同时MPA对单核细胞释放肿瘤坏死因子α(TNF α)、干扰素γ(IFN γ)和白细胞介素1(IL-1)等细胞因子均有明显的抑制作用。因此,MMF 可以通过抑制过强的免疫反应发挥其治疗重型肝炎的作用。我国慢性重型肝炎最常见的病因是乙型肝炎病毒(HBV)感染。我们在初步证明了MMF的活性代谢产物MPA能抑制HBV复制和对小鼠免疫性肝损伤有保护作用的基础上,将MMF试用于重型肝炎患者的治疗,取得初步疗效,为临床重型肝炎的治疗进行了有益的探索。
Mycophenolate mofetil (MMF), a 2-acetyl derivative of mycophenolic acid (MPA), is a novel immunosuppressant that selectively inhibits proliferative T and B lymphocytes and thus inhibits humoral and cellular immunity . At the same time, MPA could significantly inhibit the release of cytokines such as TNFα, IFNγ and IL-1 from monocytes. Therefore, MMF can play its role in the treatment of severe hepatitis by inhibiting excessive immune response. The most common cause of chronic severe hepatitis in our country is Hepatitis B virus (HBV) infection. Based on the preliminary evidence that MPA, an active metabolite of MMF, can inhibit HBV replication and protect mice against immunological liver injury, we tried MMF in the treatment of patients with severe hepatitis and achieved initial therapeutic effects for the treatment of clinical severe hepatitis Conducted a useful exploration.